CIPLA.BO
Price
Fundamentals
Valuation & profitability ratios
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $275.48B | $257.74B | $227.53B | $217.63B |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $52.73B | $41.22B | $28.02B | $25.17B |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | $52.73B | $41.22B | $28.02B | $25.17B |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Dec 2025 | 15.55 | 10.94 | -29.7% |
| Sep 2025 | 16.34 | 16.72 | +2.3% |
| Jun 2025 | 14.66 | 16.06 | +9.6% |
| Mar 2025 | 12.90 | 15.12 | +17.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 11.05 | 4 | $67.11B | -0.3% |
| Next quarter | 12.65 | 2 | $70.97B | +2.0% |
| Current year | 52.51 | 32 | $283.42B | +2.9% |
| Next year | 56.65 | 36 | $308.84B | +9.0% |
Analyst targets & ownership
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Dec 2, 24 | Hamied (Rumana) Promoter |
— | 4.94M | — | Direct |
| Dec 2, 24 | Hamied (Samina) Promoter |
— | 8.95M | — | Direct |
| Aug 21, 24 | Jain (Anusha Dinesh) UNREPORTED |
SELL | 2.00K | $37.94K | Direct |
| Aug 12, 24 | Jain (Anusha Dinesh) UNREPORTED |
SELL | 3.00K | $56.76K | Direct |
| Jul 24, 24 | HDFC Mutual Fund Institution- Corporation |
— | 198.73K | — | Direct |
| May 15, 24 | Hamied (Rumana) Promoter |
— | 4.94M | — | Direct |
| May 15, 24 | Hamied (Samina) Promoter |
— | 8.95M | — | Direct |
| May 15, 24 | Hamied (Shirin) Promoter |
— | 6.36M | — | Direct |
| May 15, 24 | Okasa Pharma, Pvt. Ltd. Promoter |
— | 189.38K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
HDFC Mutual Fund |
Institution- Corporation | 40.34M | Acquisition |
Hamied (Rumana) |
Promoter | 0 | Sale |
Hamied (Samina) |
Promoter | 0 | Sale |
Hamied (Shirin) |
Promoter | 0 | Sale |
Jain (Anusha Dinesh) |
UNREPORTED | 15.42K | Sale |
Okasa Pharma, Pvt. Ltd. |
Promoter | 0 | Sale |
Moving averages & technicals
Risk profile
Unusual options activity
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.